Bruker Corp (NASDAQ:BRKR) reported mixed fourth-quarter financial results on Thursday.
Bruker reported quarterly earnings of 59 cents per share which missed the analyst consensus estimate of 65 cents per share. The company reported quarterly sales of $977.200 million which beat the analyst consensus estimate of $960.834 million.
Bruker said it sees FY2026 adjusted EPS of $2.10-$2.15, versus market estimates of $2.13. The company sees sales of $3.570 billion-$3.600 billion versus estimates of $3.470 billion.
Frank H. Laukien, Bruker’s President and CEO, said: “At the conclusion of a difficult year 2025, with headwinds from academic funding, tariffs and currencies, we are pleased that in the fourth quarter we delivered revenues ahead of our expectations. A recovery in biopharma and industrial research markets in the second half of the year, as well improvements in semiconductor orders enabled our Scientific Instruments segment to achieve a book-to-bill ratio greater than 1.0x for the second quarter in a row, while our BEST segment booked strong multi-year orders.”
Bruker shares rose 1.6% to trade at $43.27 on Friday.
These analysts made changes to their price targets on Bruker following earnings announcement.
- Barclays analyst Luke Sergott maintained Bruker with an Overweight rating and lowered the price target from $55 to $50.
- TD Cowen analyst Dan Brennan maintained the stock with a Hold and lowered the price target from $53 to $43.
Considering buying BRKR stock? Here’s what analysts think:
Photo via Shutterstock